Johnson & Johnson has applied for registration of the COVID-19 vaccine in the United States
Johnson & Johnson Corporation has applied for registration of a coronavirus vaccine in the United States.
“Johnson & Johnson announces that Janssen Biotech (part of the corporation) has filed an application with the U.S. Food and Drug Administration (FDA) requesting emergency use of its single – component vaccine,” the press release said.
Johnson & Johnson reported in late January that its single-component vaccine showed 72% effectiveness in the U.S. and 66% overall in preventing moderate to severe COVID-19 28 days after vaccination. To prevent a severe course, the effectiveness was 85%, 28 days after its administration, it demonstrated complete protection against hospitalization due to coronavirus and from death due to this cause.
The COVID-19 vaccine produced by Janssen, part of the Johnson & Johnson holding, is made on the basis of a weakened adenovirus that causes an immune response in the human body. It is noted that this vaccine does not require a repeated dose and can be stored in freezers for several months.
In the US, anti-coronavirus vaccines from Pfizer-BioNTech and Moderna-have so far been officially approved.